Personal profile
Personal profile
Elizabeth R. Plimack is a Professor of Medical Oncology and the Deputy of Director Fox Chase Cancer. She is an expert on the treatment of genitourinary malignancies with a focus on bladder and kidney cancers. Her research effort is directed towards the discovery of novel therapeutic approaches and predictive biomarkers for patients with bladder and kidney cancers.
Dr. Plimack has extensive clinical trial experience with targeted therapy, immunotherapy and novel combination therapies. She serves on the National Comprehensive Cancer Network guidelines panels for Bladder Cancer, chairs the Scientific Advisory Board of the Bladder Cancer Advocacy Network Management and is an elected member of the American Society of Clinical Oncology Board of Directors (2020-2024) who elected her as Treasurer for 2023-2024. Dr. Plimack has mentored numerous students, residents and fellows and has been among the faculty at the annual AACR/ASCO Methods in Clinical Cancer Research workshop since 2022.
Dr. Plimack received her undergraduate degree from Yale University and completed her M.D. degree and residency in Internal Medicine at the New York University School of Medicine. She went on to a Medical Oncology Fellowship at the MD Anderson Cancer Center, and received a Master’s in Patient Based Biologic Research from the University of Texas Graduate School of Biomedical Science.
Professional Information
Treatment Philosophy
With a diagnosis of cancer comes uncertainty and fear for many patients. As a medical oncologist, my first job is to help each patient understand his or her diagnosis. With that understanding, together we can design the best plan of action. At Fox Chase, each patient has the benefit of an interdisciplinary team working together to ensure the highest quality care. This interdisciplinary approach is crucial in determining and implementing the best treatment plan.
I specialize in the treatment of kidney, bladder, prostate and testicular cancer, and my clinical practice is focused on these diseases. By concentrating exclusively on genitourinary malignancies I am able to offer expert knowledge as well as access to both standard treatments and emerging therapies in the form of clinical trials. The pace of scientific discovery has accelerated in recent decades, and fortunately we have seen these discoveries translate into meaningful improvements in cancer treatments.
As part of the genitourinary group here at Fox Chase, I am proud to be a part of a team of distinguished researchers who have pioneered many of these new treatments. My particular research efforts focus on the development of new therapies for bladder and kidney cancer.
Areas of Expertise
Kidney Cancer, Urethral Cancer, Bladder Cancer, Ureteral Cancer, Prostate Cancer
Research interests
- Biomarkers predictive of response to neoadjuvant cisplatin based chemotherapy in bladder cancer
- Refining neoadjuvant chemotherapy regimens for bladder cancer
- Developmental Therapeutics – early stage clinical trials of novel agents
- Immunotherapy in GU Malignancies
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Assessing Treatment Outcomes of Patients Undergoing Enfortumab Vedotin Dose Reduction in Metastatic Bladder Cancer
Rives, H., Fredette, J., Anari, F., Ghatalia, P., Geynisman, D., Plimack, E. & Zibelman, M., Mar 3 2026, (E-pub ahead of print) In: Clinical Genitourinary Cancer.Research output: Contribution to journal › Article › peer-review
-
Assessing Treatment Outcomes of Patients Undergoing Enfortumab Vedotin Dose Reduction in Metastatic Bladder Cancer
Rives, H., Fredette, J., Anari, F., Ghatalia, P., Geynisman, D., Plimack, E. & Zibelman, M., 2026, (Accepted/In press) In: Clinical Genitourinary Cancer. 102525.Research output: Contribution to journal › Article › peer-review
-
Gender Disparities in Citations and Altmetric Attention Score in Oncology
Campbell, R. A., Helstrom, E., Chew, L., Eapen, R., Plimack, E., Correa, A., Kutikov, A., Abbosh, P., Calaway, A., Nizam, A., Gupta, S., Psutka, S. P., Barata, P., Dizman, N., Sindhani, M., Weight, C. J. & Bukavina, L., Feb 2026, In: JCO Oncology Practice. 22, 2, p. 332-341 10 p., OP-24-00767.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial
Choueiri, T. K., Albigès, L., McDermott, D. F., Hammers, H. J., Escudier, B., Burotto, M., Plimack, E. R., Porta, C., George, S., Powles, T., Donskov, F., Atkins, M. B., Gurney, H., Kollmannsberger, C. K., Grimm, M.-O., Barrios, C., Castellano, D., Grünwald, V., Tomita, Y. & Rini, B. I. & 5 others, , Mar 3 2026, (E-pub ahead of print) In: Annals of oncology : official journal of the European Society for Medical Oncology.Research output: Contribution to journal › Article › peer-review
-
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial☆
Choueiri, T. K., Albigès, L., McDermott, D. F., Hammers, H. J., Escudier, B., Burotto, M., Plimack, E. R., Porta, C., George, S., Powles, T., Donskov, F., Atkins, M. B., Gurney, H., Kollmannsberger, C. K., Grimm, M. O., Barrios, C., Castellano, D., Grünwald, V., Tomita, Y. & Rini, B. I. & 5 others, , 2026, (Accepted/In press) In: Annals of Oncology.Research output: Contribution to journal › Article › peer-review
Open Access
Prizes
-
Fellow of the American Society of Clinical Oncology
Plimack, E. R. (Recipient), Nov 9 2023
Prize: Other distinction
Press/Media
-
Reports from Fox Chase Cancer Center Add New Data to Findings in Oncology (Gender Disparities in Citations and Altmetric Attention Score in Oncology)
Plimack, E. R., Kutikov, A., Correa, A. F. & Abbosh, P.
02/23/26
1 item of Media coverage
Press/Media
-
Philadelphia Magazine Names 142 Fox Chase Cancer Center Physicians 'Top Doctors'
Mantia-Smaldone, G. M., Vijayvergia, N., Borghaei, H., Weiss, S. E., Kumar, R., Khanal, R., Frosch, Z. A., Flieder, D. B., Chen, D. Y., Plimack, E. R., Manley, C. J., Nejati, R. M., Ehya, H., Kutikov, A., Sherry, D. R., Hallman, M. A., Uzzo, R. G., Patel, S. A., Daly, M., Viterbo, R., Curcillo, P. G., Bleicher, R., Edelman, M., Greco, S. H., Miyamoto, C. T., von Mehren, M., Chwistek, M., Galloway, T. J., Jain, A., Meyer, J. E., Castellanos, J. A., Farma, J. M., Weinberg, D. S., Friedberg, J., Wasik, M. A., Zibelman, M. R., Wang, Y. L., Astsaturov, I., Olszanski, A. J., Simhan, J., Friedlander, J. I., Cohn, J., Sterious, S., Wei, S., Giri, A. P., Berman, A. T., Loren, D. E., McCue, P. A., Abdelmessieh, P., Ahmad, D., Messmer, M., Ghiraldi, E. M., Horwitz, E. M., Correa, A. F., Yu, J. Q., Smaldone, M. C., Villano, A. M., Aphale, A., McShane, M. M., Kumar, S. S., Walchak, A., Wookey, V. B., Wong, J. K., Nakhoda, S. K., Bauman, J., Williams, A. D., Hall, M. J., Fung, H. C., Reddy, S. S. & Geynisman, D.
04/22/25
1 item of Media coverage
Press/Media
-
Adjuvant nivolumab delivers in muscle-invasive bladder cancer
03/9/25
1 item of Media coverage
Press/Media
-
Correlative analysis from HCRN GU16-260 study published in Cancer Discovery
02/27/25
1 item of Media coverage
Press/Media